EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria

Afif Nakhleh iD, Muhammad Abdul-Ghani iD, Sivan Gazit, Adi Gross, Idit Livnat, Maya Greenbloom, Adva Yarden, Khaled Khazim, Naim Shehadeh, Cheli Melzer Cohen iD

Diabetes, Obesity and Metabolism · 2024-08 · 26 (8) · 3058-3067

DOI: 10.1111/dom.15623 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 28.04.2024. Verfasst von Afif Nakhleh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes and Endocrinology Clinic, Maccabi Healthcare Services, Haifa, Israel. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency, Chronic, Albuminuria, Disease Progression. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To examine the renal effects of sodium‐glucose cotransporter‐2 (SGLT2) inhibition among non‐diabetic individuals with chronic kidney disease (CKD) in a real‐world setting.

Methods

We collected de‐identified data on adults without diabetes and with an estimated glomerular filtration rate (eGFR) of 25–60 mL/min/1.73 m 2 , who initiated the SGLT2 inhibitors dapagliflozin or empagliflozin between September 2020 and November 2022 at Maccabi Healthcare Services, an Israeli health maintenance organization. We assessed the effects of SGLT2 inhibitors on renal function (changes in eGFR slope/time). Index date was defined as the date of the first dispensing of SGLT2 inhibitors. Annual baseline slope was calculated using all eGFR measurements during the 2 years prior to index date (median = 7 measurements), while annual follow‐up slope was calculated from all evaluations during 90–900 days post index date, along with baseline measurement at index date (median = 6 measurements). Paired t tests were used to compare differences between baseline and follow‐up annual slopes.

Results

Of a total of 354 participants with CKD, without diabetes, who received SGLT2 inhibitors and were followed for a median of 527 days, the mean age was 72.8 ± 11.8 years, 26% were female, and 91% used renin‐angiotensin system blockade. The mean eGFR was 45.4 ± 9.5 mL/min/1.73 m 2 . The mean body mass index was 29.1 ± 5.4 kg/m 2 . During the year before index date, 146 participants (41%) had a urinary albumin to creatinine ratio (UACR) 300 mg/g, and 53 (15%) had no UACR evaluation. The mean eGFR slope over time was −5.6 ± 7.7 mL/min/1.73 m 2 per year at baseline, which improved to −1.7 ± 6.8 mL/min/1.73 m 2 per year after SGLT2 inhibitor administration ( p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsRenal Insufficiency, ChronicAlbuminuriaDisease ProgressionGlomerular Filtration RateBenzhydryl CompoundsGlucosidesHumansFemaleMaleMiddle AgedAgedIsraelTreatment OutcomeDiabetes Mellitus, Type 2

Stichwörter der Autor:innen

CKDSGLT2 inhibitorseGFR slope

Substanzen

Sodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsGlucosidesdapagliflozinempagliflozin

Autor:innen und Institutionen

  • Diabetes and Endocrinology Clinic, Maccabi Healthcare Services, Haifa, Israel.
  • Institute of Endocrinology, Diabetes and Metabolism, Rambam Health Care Campus, Haifa, Israel.
  • Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
  • Division of Diabetes, University of Texas Health Science Centre, San Antonio, Texas, USA.
  • Maccabi Institute for Research and Innovation, Tel-Aviv, Israel.
  • Medical Affairs, AstraZeneca, Kfar Saba, Israel.

ORCID-Profile: Afif Nakhleh, Muhammad Abdul-Ghani, Cheli Melzer Cohen

Förderung

  • AstraZeneca

Zitieren

APA

Nakhleh, A., Abdul-Ghani, M., Gazit, S., Gross, A., Livnat, I., Greenbloom, M., Yarden, A., Khazim, K., Shehadeh, N., & Melzer Cohen, C. (2024). Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria. Diabetes, Obesity and Metabolism, 26(8), 3058-3067. https://doi.org/10.1111/dom.15623

Vancouver

Nakhleh A, Abdul-Ghani M, Gazit S, Gross A, Livnat I, Greenbloom M, et al. Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria. Diabetes, Obesity and Metabolism. 2024;26(8):3058-3067. doi:10.1111/dom.15623

BibTeX
@article{Nakhleh2024,
  author = {Nakhleh, Afif and Abdul-Ghani, Muhammad and Gazit, Sivan and Gross, Adi and Livnat, Idit and Greenbloom, Maya and Yarden, Adva and Khazim, Khaled and Shehadeh, Naim and Melzer Cohen, Cheli},
  title = {Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  volume = {26},
  number = {8},
  pages = {3058--3067},
  doi = {10.1111/dom.15623}
}
Kostenlos starten →